anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To stabilize a coloring matter with an extract of a myricaceous plant. CONSTITUTION:An extract of a myricaceous plant, obtd. by extracting the plant with water or a 1-5C aliph. alcohol and removing tannin from the resulting extract, is more effective in stabilizing a tar-derived coloring matter, a natural coloring matter deriv., a natural-synthetic coloring matter, and a natural coloring matter including carotenoid, anthocyanin, anthraquinone, betaine, flavonoid, monascus and other various coloring matters than a synthetic antioxidant or tocopherol. Foods, drugs, quasi drugs, cosmetics, or feeds contg. the extract do not exhibit the degradation in quality due to discoloration caused by light or aging.
This is a first-in-humans, phase 1, randomized, double-blind, single-site, placebo-controlled study in 104 healthy volunteers, males and females, aged 18 to 45 years inclusive. The study will consists of 3 parts: Part 1, Single Ascending Dose (SAD) - participants will be administered a single dose (ranges from 9 mg to 900 mg) of DM1157 orally after fasting or a matching placebo; Part 2, Multiple Ascending Dose (MAD) - participants will be administered three doses (ranges from 150 mg to 900 mg) of DM1157 orally once daily for three days after fasting or a matching placebo; and Part 3, Food Effect - participants will be administered 300 mg of DM1157 orally with high fat meal or a matching placebo. Part 2 and Part 3 may be initiated after a Safety Monitoring Committee (SMC) review and approval of the of Part 1 safety data. Study duration will be 16 months with patient participation duration 14 days for SAD and Food Effect, and 18 days for MAD. The primary objectives of this study are to: 1) assess the safety and tolerability of single doses of DM1157 at levels ranging from 9 mg to 900 mg; 2) assess the safety and tolerability of DM1157 administered as single daily doses for 3 days at levels ranging from 150 mg to 900 mg; 3) assess the safety and tolerability of DM1157 administered with or without food. The secondary objectives are to: 1) assess the PK of single doses of DM1157 at levels ranging from 9 mg to 900 mg, including dose proportionality; 2) assess the PK of DM1157 administered as single daily doses for 3 days at levels ranging from 150 mg to 900 mg; 3) assess the PK of 300 mg DM1157 administered with or without food, including determination of the presence or absence of a food effect on exposure.
CBIT certified clinicians will train OTs in delivering CBIT to affected youth. OTs will be supervised in the practice of CBIT with youth in the New York City and Birmingham areas. Pre- and post-treatment assessment measures will be collected from 16 families (8 from each site) to evaluate intervention acceptability, feasibility, and fidelity. Patient and parent satisfaction of CBIT-OT will also be documented.
Patients will receive standard high dose of IL2 (HD-IL-2) after receiving standard lymphodepleting chemotherapy and TIL product. In the control arm, the first i.v. dose of HD-IL2 will be administered within 3-24 hours after TIL infusion, and thereafter every 8 hours to tolerance up to a maximum of 6 doses.
A rigid, water-soluble container for fabric care, surface care (eg cleaning or polishing of surfaces) or dishwashing compositions is made of a cellulose ether. It may be injection moulded and may comprise hydroxypropylmethylcellulose. The container may as shown comprise a generally cuboid receptacle part, optionally divided into compartments, which is closed by a water-soluble closure in the form of a film, optionally of poly (vinyl alcohol). Alternatively, the container may be of a capsule shape (Figures 8-13) comprising a receptacle part and a rigid closure part. In all cases, the closure may dissolve before the receptacle. A plurality of the cuboid containers may be separably joined together in a side-by-side array, especially for use in washing.
BACKGROUND: Sepsis often leads to significant morbidity and mortality due to severe myocardial injury. As is known, the activation of NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome crucially contributes to septic cardiomyopathy (SCM) by facilitating the secretion of interleukin (IL)-1β and IL-18. The removal of palmitoyl groups from NLRP3 is a crucial step in the activation of the NLRP3 inflammasome. Thus, the potential inhibitors that regulate the palmitoylation and inactivation of NLRP3 may significantly diminish sepsis-induced cardiac dysfunction.
PURPOSE: The present study sought to explore the effects of the prospective flavonoid compounds targeting NLRP3 on SCM and to elucidate the associated underlying mechanisms.
STUDY DESIGN: The palmitoylation and activation of NLRP3 were detected in H9c2 cells and C57BL/6 J mice.
METHODS/RESULTS: Echocardiography, histological staining, western blotting, co-immunoprecipitation, qPCR, ELISA and network pharmacology were used to assess the impact of vaccarin (VAC) on SCM in mice subjected to lipopolysaccharide (LPS) injection. From the collection of 74 compounds, we identified that VAC had the strongest capability to suppress NLRP3 luciferase report gene activity in cardiomyocytes, and the anti-inflammatory characteristics of VAC were further ascertained by the network pharmacology. Exposure of LPS triggered apoptosis, inflammation, oxidative stress, mitochondrial disorder in cardiomyocytes. The detrimental alterations were significantly reversed upon VAC treatment in both septic mice and H9c2 cells exposed to LPS. In vivo experiments demonstrated that VAC treatment alleviated septic myocardial injury, indicated by enhanced cardiac function parameters, preserved cardiac structure, and reduced inflammation/oxidative response. Mechanistically, VAC induced NLRP3 palmitoylation to inactivate NLRP3 inflammasome by acting on zDHHC12. In support, the NLRP3 agonist ATP and the acylation inhibitor 2-bromopalmitate (2-BP) prevented the effects of VAC.
CONCLUSION: Our findings suggest that VAC holds promise in protecting against SCM by mitigating cardiac oxidative stress and inflammation via priming NLRP3 palmitoylation and inactivation. These results lay the solid basis for further assessment of the therapeutic potential of VAC against SCM.
Stryker Orthopaedics N2Vac Polyethylene when used with a Triathlon Posterior Stabilized total knee system. This is a fixed- bearing knee intended for use in patients undergoing cemented total knee arthroplasty.
OBJECTIVE: Bridging stentgrafts (BSGs) are one of the primary limiting factors regarding long-term results after fenestrated endovascular aortic repair (fEVAR). This study aims to report for the first time the outcome of a novel BSG called iCover from a national, multicentric retrospective database.
METHODS: A cohort of 58 patients received 212 BSGs for the renovisceral arteries in fEVAR. Patients were followed-up clinically and with computed-tomography angiography. Study end points were mortality, occurrence of complications, technical success of the BSG implantation, defined as successful deployment with vessel patency and absence of type 1c, 3b, and 3c endoleak, and stability over the follow-up.
RESULTS: Three BSG unrelated mortalities (5.1 %), four BSG unrelated major complications (6.8 %) and five minor complications (8.6 %) occurred. The technical success of iCover was 207/212 (97.6 %), target vessel patency was 100 % over a follow-up of 4.0 months, and no late BSG related endoleak was detected. In two cases, the BSG was dislodged from the balloon and could be parked in a safe position without further sequelae (0.9 %).
CONCLUSION: The iCover represents a feasible BSG for fEVAR with an excellent safety profile and technical success rate in the early phase. Prudent post-dilatation and monitoring of the proximal and distal stent ends can potentially further improve outcome. Longer follow-up series are necessary.
PURPOSE:To obtain a cross-linked hyaluronic acid material improved in respect of toxicity and gel strength and having a high strength and a variety of decomposition and absorption rates, by mixing an aq. soln. of hyaluronic acid with a carbodiimide and drying the aq. soln. to introduce thereinto cross-linkages. CONSTITUTION:An aq. soln. of hyaluronic acid is mixed with a carbodiimide, and then dried to introduce thereinto cross-linkages to thereby obtain the desired cross-linked hyaluronic acid material. The mol.wt. of hyaluronic acid to the used is usually about 10<6> to 2X10<6>. Hyaluronic acid may be used either in the form of a free acid or in the form of a salt of an alkali metal such as sodium or potassium, or an alkaline earth metal such as calcium or magnesium. The carbodiimide is desirably a water-soluble carbodiimide from the viewpoint of removal treatment thereof during and after the cross-linking reaction, though a carbodiimicle soluble only in an org. solvent, such as dicyclohexylcarbodiimicle, may instead be used.
OBJECTIVES: To evaluate the complication rate, mortality rate and putative risk factors for cecal or colonic surgery in dogs.
MATERIALS AND METHODS: A multi-institutional retrospective study including dogs that had undergone surgery that involved the cecum or the colon. Medical records from three referral hospitals were reviewed for patient demographics and clinical data. The association between putative risk factors and survival to discharge or complications was assessed using univariable and multivariable analysis.
RESULTS: Seventy-nine dogs met the criteria to be included in this study. Fifty-five dogs had full thickness incision surgeries, while 24 dogs had partial thickness surgeries. The complication and mortality rates for full thickness and partial thickness cecal/colonic surgeries were not statistically different. The dehiscence rate of colonic anastomosis in this study was four of 47 (8.5%). On univariate analysis, performing full thickness procedures out of hours had an association with increased complications and mortality. On multivariable analysis, no factors were associated with survival to discharge or complications. There was no association of board-certified surgeon presence in surgery with complications or mortality.
CLINICAL SIGNIFICANCE: The performance of full thickness cecal/colonic surgery is not associated with a statistically significant increased risk for complications or mortality compared to partial thickness procedures, with a possible increased risk of complications and mortality in full thickness procedures out of hours.
1. An isolated sequence of the DNA molecule which encodes L1 capsid protein of the human papillomavirus type 18 having the following structure:     2. An isolated sequence of the DNA molecule which encodes L2 capsid protein of the human papillomavirus type 18 having the following structure:      3. An expression vector for sequence of the DNA molecule according claim 1 and 2 of formula in a host cells, constructed on the base of yeast shuttle vector, including pBR322, yeast gene LEU2d and yeast 2μ-plasmide , and comprising SpHI-moety having the size of 1,4 th.b.p. from pUC18 plasmide, including the following constructive elements: divergent promoters S. cerevisiae GAL1-GAL10 from pBM272 plasmide, which are flanked from each side by the terminator copy ADHI transcription; BamHI-cloning site, located between GAL1 promotor and the terminator first copy ADHI transcription; and SmaI-cloning site, located between GAL10 promotor and the terminator second copy ADHI transcription. 4. An expression vector according claim 3, characterised in that it represents vector p191-6, comprising sequence of the DNA molecule as claimed in claim 1 of the formula, inserted BamHI-cloning site. 5. An expression vector according claim 3, characterised in that it represents vector p195-11, comprising sequence of the DNA molecule as claimed in claim 1 of the formula, inserted BamHI-cloning site, and sequence of the DNA molecule as claimed in claim 2 of the formula, built in SmaI-cloning site. 6. A method of producing the virus-like particles of the human papillomavirus type 18, comprising the following steps: (a) transforming yeast cells with expression vector in accordance with any of claims 3-5 of the formula; (b) cultivating the transformed cells under conditions that permit expression of the sequence of DNA molecule, encoding L1 protein and L1+L2 the human papillomavirus type 18 proteins; and  (c) isolating the virus-like particles, which spontaneously form in a cell after expression in it of the above-mentioned proteins. 7. A method for inducing an immune response to papillomaviruses in an animal comprising administering the virus-like particles produced in accordance with claim 6 to an animal.
In addition to the base program and supplementary communication, members of the Direct Payment group received a gift voucher, corresponding to their level of engagement. Members received payouts at the end of each month of registration, for 5 different levels of engagement. The payout for the lowest level of engagement corresponded to about 25% of the monthly subscription for the wellness program. The payout for the highest level of engagement was 3 times more than the monthly subscription for the wellness program. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
Use of a surface active phospholipid in the manufacture of a powder medicament for the treatment of wet lung in mammals. Wet lung is a condition in which there is slow and incomplete clearance of lung fluid and may occur in respiratory distress syndrome (RDS) including infant respiratory distress syndrome (IRDS) and acute respiratory distress syndrome (ARDS). ARDS is a pulmonary complication which may follow a variety of disorders including sepsis, trauma and shock. The medicament is preferably in the form of a dry, finely-divided solid which is a blend of a first component consisting of one or more phosphatidyl cholines and a second component which is one or more of phosphatidyl glycerols, phosphatidyl ethanolamines, phosphatidyl serines, phosphatidyl inositols and chlorestyl palmitate, preferably a blend of phosphatidyl choline and phosphatidyl glycerol. Preferably the phosphatidyl choline is dipalmitoylphosphatidyl choline. The SAPLs may be prepared synthetically and the phosphatidyl choline, dipalmitoylphosphatidyl choline and/or phosphatidyl glycerol may comprise the dextro-rotatory form.
A self-contained RFID-enabling drawer module includes a probe antenna to introduce a robust EM field into a container within a Faraday cage to activate RFID tags within the container, regardless of the container's resonant frequency. A receiving antenna and reader read the data of the activated RFID tags, and a processor and communications module transmit the RFID tag data to a remote processor. The RFID-enabling module is self-contained in that it needs only power and a data connection with which to operate. Where an Ethernet is used, power is obtained by PoE. The RFID-enabling module may be used to retrofit existing medication drawers of a medication cabinet or may be used during the construction of a new cabinet. The RFID-enabling system includes auto tuning of the antenna to dynamically compensate for loading changes on the EM field. Assembly and testing costs are reduced and serviceability of the system is increased.
The goal of the study is to pin down the causal effect of improvements in health on the economic and social prosperity of individuals and their families. Particular attention will be paid to the dynamics underlying the effect of health on labor outcomes; older adults are more likely to experience transitions in health and economic status and so will be emphasized.

Beginning in 2002, about 4,000 households will be interviewed every four months for about 3 years. The first two waves of the survey will serve as baselines. After the second wave, households will be randomly assigned to one of two groups. Iron supplements will be provided to all members of households assigned to one of those groups. Household members in the 2nd group will receive an identical-looking placebo. Participants will take the supplements (or placebo) on a weekly basis for a year. The study will measure the effect of supplementation on the well-being of individuals and their families.

Data will be collected at the individual, household and community level. Individual level data will cover time allocation including work and participation in community activities, earnings, self-reported and physical health and cognition. All adult household members will be interviewed; questions about children will be answered by a caretaker. Data on wealth and consumption will be collected at the household level. Community resources, services and infrastructure information will be gathered along with detailed price data.
The Transversus Abdominis Plane Block was not performed. Intravenous PCA Morphine was given as rescue analgesic upto 24 hours.
The present disclosure belongs to the field of health care products, disclosing a powder made from xylo-oligosaccharide, isomaltooligosaccharide, mannitol, synanthrin, Codonopsis Radix, Hericium erinaceus polysaccharide, Dioscoreae Rhizoma, Poria, Semen Dolichoris Album, Citri Reticulatae Pericarpium, Amomi Fructus and Atractylodis Macrocephalae Rhizoma. The raw materials of the powder are all from natural Chinese herbal medicine without addition of excipient. It is clean and has natural components, in line with people's pursuit of natural and health foods. In addition, dosage required for the powder is small; it can be taken orally or dissolved in water; it is soluble in cold water and melts in mouth; it has a good taste and can be absorbed quickly. The method for preparing the powder in the present disclosure is simple and suitable for large-scale production. Also, it is easy to be carried. The powder obtained has a good stability and long storage time. Experiments show that the powder of the present disclosure can improve gastric mucosal injury, effectively reduce the acute gastric mucosal injury caused by ethanol, and has a good regulatory effect on intestinal flora, therefore can be used to prepare the health care foods having functions on regulating gastrointestinal tract and protecting gastric mucosa.
Approximately 29 participants will be randomized in a 5:2 ratio (cohorts 1, 2, and 3) or in a 3:1 ratio (cohorts 4 and 5) to Efavaleukin Alfa or placebo in addition to standard of care therapy. Efavaleukin Alfa or placebo will be administered either weekly (QW) or biweekly (Q2W).
According to the present invention, a method for enhancing transdermal transport is disclosed. The method includes the steps of increasing a permeability of an area of a membrane with a permeabilizing device. The membrane may be, inter alia, biologic skin or synthetic skin. The permeabilizing device may be an ultrasound-producing device. A substance is transported into and through the area of the membrane. The substance may be a drug, a vaccine, or a component of interstitial fluid.
Participants assigned to the oseltamivir phosphate treatment arm will receive the appropriate weight-based dose of oseltamivir phosphate every 12 hours for 10 doses. For children 0-11 months of age, oseltamivir phosphate will be dosed as 3mg/kg/dose every 12 hours. For children 12 months and older, oseltamivir phosphate will be dosed as follows: 30 mg every 12 hours for children up to 15kg, 45mg every 12 hours for children greater than 15kg up to 23 kg, 60mg every 12 hours for children greater than 23 up to 40kg, and 75mg every 12 hours for children greater than 40kg.
The tilting window has a geared setting-rod-linkage unit moving below a sheathing rail, a bolting member moved across one of them, and a stop lug. There is provision for security in case of faulty operation. With the window open, the bolting member is moved by spring force to a position with one its stops held in the lug track, and when closed it is held against the blind frame in a release position. When the system is ready for installation there are two springs (16, 17) loading the bolting member (22), optionally removable and acting opposite ways. The unit is preferably mounted on the top horizontal shank of the wing. This can be easily fitted to operate on either side, involving only removal of one of the two springs.
This group will keep the routine treatment in outpatient of bariatric surgery. This treatment consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.
The present invention relates to a traditional Chinese medicine for treating subhyaloid hemorrhage which is caused by yin deficiency, liver-yang hyperactivity and network vessel thermal injury and a preparation method thereof. Subhyaloid hemorrhage refers to retinal hemorrhage which is caused by various reasons. Medicines which are frequently used in clinics at present comprise inositol nicotinate, tolazoline, entodon, potassium iodide, heparin, urokinase, etc. However, the clinic effect is not satisfactory. The present invention is composed of the twelve traditional Chinese medicines of red sage root, rehmanniae, yerbadetajo herb, motherwort fruit, notoginseng, red peony root, tree peony bark, glossy privet fruit, common selfheal fruit-spike, pubescent holly root, rhubarb, tuckahoe, etc. In the prescription, the red sage root, the notoginseng, the red peony root, etc. have the functions of promoting blood circulation and removing blood stasis, the motherwort fruit, the glossy privet fruit and the common selfheal fruit-spike perform the functions of nourishing yin and improving the acuity of vision by clearing the vacuity heat of the liver, the cortex moutan and the baical skullcap root have the function of cooling blood by clearing the vacuity heat of the liver and the lung, and the rehmanniae and the yerbadetajo herb have the efficacy of removing stasis, arresting hemorrhage, nourishing yin, clearing the liver and improving the acuity of vision by nourishing the yin of the liver and the kidney. Clinic 300 cases verify that the traditional Chinese medicine has significant therapeutic effect, the total effective rate is 92.67%, and the traditional Chinese medicine is safe and effective without adverse reaction or side effect.
Stomatitis, including mouth ulcers and oral mucositis, has occurred in patients treated with everolimus tablets at an incidence ranging from 44% to 78% across clinical trials. Grades 3-4 stomatitis was reported in 4% to 9% of patients [see Adverse Reactions (6.1)]. Stomatitis most often occurs within the first 8 weeks of treatment. When starting everolimus tablets, initiating dexamethasone alcohol-free oral solution as a swish and spit mouthwash reduces the incidence and severity of stomatitis [see Adverse Reactions (6.1)]. If stomatitis does occur, mouthwashes and/or other topical treatments are recommended. Avoid alcohol-, hydrogen peroxide-, iodine-, or thyme- containing products, as they may exacerbate the condition. Do not administer antifungal agents, unless fungal infection has been diagnosed.
Patients agreeing to participate in the research study will receive an additional intravenous injection during endoscopy. This dose of 2.5 mg of IV fluorescein will be administered during their EGD. Probe-based microscopy will be used to evaluate the mucosa of the esophagus and GE junction. Photographs will be taken and digitally stored. Biopsies (which are part of the routine diagnosis and surveillance of Barrett's) will be targeted based on the microscopic images. The histologic findings on the biopsy specimens will be compared to the microscopic images to determine the accuracy of the probe-based microscopy in predicting pathology.
Participants will use the NEAT! smartphone application and accelerometer over a 1 month period.